Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC
Marina Chiara Garassino(University of Chicago), Luis Paz‐Ares(Hospital Universitario 12 De Octubre), Shirish M. Gadgeel(Chinese University of Hong Kong), Bilal Piperdi(Université Toulouse III - Paul Sabatier), Delvys Rodríguez‐Abreu(Universidad de Las Palmas de Gran Canaria), Julie Kobie(Merck & Co., Inc., Rahway, NJ, USA (United States)), Edward B. Garon(University of California, Los Angeles), Martin Reck(German Center for Lung Research), Andrey Loboda(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jared Lunceford(Merck & Co., Inc., Rahway, NJ, USA (United States)), Răzvan Cristescu(Merck & Co., Inc., Rahway, NJ, USA (United States)), M. Catherine Pietanza(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hidehito Horinouchi(Tokyo National Hospital), Deepti Aurora-Garg(Merck & Co., Inc., Rahway, NJ, USA (United States)), Shunichi Sugawara(Sendai Kousei Hospital), Balázs Halmos(Montefiore Medical Center), Enriqueta Felip(Institut Català d'Ornitologia), Giovanna Speranza(Université de Sherbrooke), Rina Hui(The University of Sydney), Silvia Novello(University of Turin), Mark Ayers(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 43
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k